

Baxter International Inc.
Net Sales
Periods Ending March 31, 2007 and 2006
(unaudited)
(\$ in millions)

	Q1 2007	Q1 2006 ¹	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience²				
United States	\$484	\$418	16%	16%
International	588	458	28%	20%
Total	\$1,072	\$876	22%	18%
Medication Delivery				
United States	\$515	\$491	5%	5%
International	475	425	12%	6%
Total	\$990	\$916	8%	6%
Renal				
United States	\$97	\$94	3%	3%
International	428	399	7%	5%
Total	\$525	\$493	6%	4%
Baxter excluding Transfusion Therapies				
United States	\$1,096	\$1,003	9%	9%
International	1,491	1,282	16%	11%
Total	\$2,587	\$2,285	13%	10%
Transfusion Therapies²				
United States	\$43	\$56	(23%)	(23%)
International	45	68	(34%)	(38%)
Total	\$88	\$124	(29%)	(31%)
Baxter International Inc.				
United States	\$1,139	\$1,059	8%	8%
International	1,536	1,350	14%	8%
Total	\$2,675	\$2,409	11%	8%

¹ Prior year sales data has been reclassified to reflect the change that is described in note 2 below.

² Sales of Transfusion Therapies (TT) products were previously reported in BioScience. Due to Baxter's expected significant continuing cash flows associated with this business, Baxter continued to include the results of operations of TT in the company's results of operations through the February 28, 2007 sale date. The amounts reported in Transfusion Therapies reflect sales of TT products until the completion of the sale of the TT business, as well as revenues associated with manufacturing, distribution and other services provided by the company to the buyer post-divestiture.